公开(公告)号：WO2021198781A2

公开(公告)日：2021-10-07

申请号：PCT/IB2021/000210

申请日：2021-04-02

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： BACHMANN, Friedmund ,  SEYFRIED, Birgit ,  GRANINGER, Michael ,  MELLGARD, Bjorn

IPC: C12N9/64

Abstract: This invention relates to ADAMTS13 variants and methods of administering ADAMTS13 variants to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction.

公开(公告)号：WO2021193984A2

公开(公告)日：2021-09-30

申请号：PCT/JP2021/014423

申请日：2021-03-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： HENNINOT, Antoine, Charles, Olivier ,  COLE, Derek, Cecil ,  SCORAH, Nicholas

IPC: C07K14/605 ,  A61K38/00 ,  A61P1/08 ,  C12N15/00

Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per day dosing (QD), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.

公开(公告)号：WO2021144649A2

公开(公告)日：2021-07-22

申请号：PCT/IB2021/000008

申请日：2021-01-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： KLUGMANN, Matthias ,  ROTTENSTEINER, Hanspeter ,  HORLING, Franziska ,  LENGLER, Johannes

IPC: A61K48/00 ,  C12N15/86 ,  A61K48/005 ,  A61K48/0058 ,  A61K48/0066 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2800/22 ,  C12N2830/008 ,  C12N2830/42 ,  C12N2830/48 ,  C12N9/0071 ,  C12Y114/16001

Abstract: The present disclosure provides, among other things, a recombinant adeno-associated virus (rAAV) vector comprising an AAV8 capsid and a codon-optimized sequence encoding a human phenylalanine hydroxylase (PAH) enzyme. The disclosure also provides a method of treating a subject having phenylketonuria (PKU), comprising administering to the subject in need thereof a recombinant adeno-associated virus (rAAV) vector comprising an AAV8 capsid, and a promoter operably linked to a nucleic acid sequence that encodes PAH, and wherein administering results in a decrease in phenylalanine level in the subject.

公开(公告)号：WO2021142083A1

公开(公告)日：2021-07-15

申请号：PCT/US2021/012447

申请日：2021-01-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  ROGGE, Mark

Inventor： FAESSEL, Helene ,  LU, Hong ,  VENKATAKRISHNAN, Karthik ,  ZHANG, Liming ,  WAGNER, John

IPC: A61K9/00 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/5377 ,  A61K45/06 ,  A61P25/00 ,  A61P25/26

Abstract: Described herein are compositions comprising (a) methyl 3 -((methyl sulfonyl)amino)-2-(((4- phenylcyclohexyl)oxy)methyl)piperidine- 1 -carboxylate or a salt thereof; and (b) an agent for reducing metabolism of (a) and uses thereof.

公开(公告)号：WO2021055326A1

公开(公告)日：2021-03-25

申请号：PCT/US2020/050823

申请日：2020-09-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  MONENSCHEIN, Holger ,  MURPHY, Sean ,  OLSEN, Scott ,  O'ROURKE, Natasha ,  REICHARD, Holly ,  DAVIS, Melinda ,  LAM, Betty

Inventor： MONENSCHEIN, Holger ,  MURPHY, Sean ,  OLSEN, Scott ,  O'ROURKE, Natasha ,  REICHARD, Holly ,  DAVIS, Melinda ,  LAM, Betty

IPC: C07D487/04 ,  A61K31/5025 ,  A61P35/00

Abstract: Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

公开(公告)号：WO2020250033A1

公开(公告)日：2020-12-17

申请号：PCT/IB2020/000443

申请日：2020-06-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： PALUMBO, Antonio ,  ALLIKMETS, Kristina ,  BERG, Deborah ,  FEDYK, Eric

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/573

Abstract: Methods of administering isolated anti-CD38 antibodies in combination with lenalidomide or pomobdomide, and dexamethasone and, optionally, bortezomib, for the treatment of multiple myeloma.

公开(公告)号：WO2020158958A1

公开(公告)日：2020-08-06

申请号：PCT/JP2020/004444

申请日：2020-01-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： HATTORI, Yasushi ,  MIYANOHANA, Yuhei ,  KAJITA, Yuichi ,  KOIKE, Tatsuki ,  HOASHI, Yasutaka ,  TOKUNAGA, Norihito ,  PAWLICZEK, Alexander Martin ,  ODA, Tsuneo ,  MIYAZAKI, Tohru ,  ITO, Yoshiteru ,  TAKEUCHI, Kohei ,  IMAMURA, Keisuke ,  SUGIMOTO, Takahiro

IPC: A61P3/00 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  C07D207/14 ,  C07D401/10 ,  C07D403/10 ,  C07D403/14 ,  C07D407/06 ,  C07D413/10 ,  C07D417/10

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：WO2020130152A1

公开(公告)日：2020-06-25

申请号：PCT/JP2019/050228

申请日：2019-12-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： EDGINGTON-MITCHELL, Laura ,  MOUNTFORD, Simon ,  ANDERSON, Bethany M. ,  SZABO, Monika ,  AURELIO, Luigi ,  THOMPSON, Philip

IPC: C09B23/08 ,  C07C381/00 ,  C07D221/18 ,  G01N33/58 ,  A61K49/00

Abstract: The present invention relates to compounds of formula I bearing a sulfoxonium ylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.

公开(公告)号：WO2020067557A3

公开(公告)日：2020-04-02

申请号：PCT/JP2019/038441

申请日：2019-09-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： IMOTO, Hiroshi ,  ADACHI, Mari ,  KANEMATSU, Yoko ,  ASAMI, Taiji ,  NIIDA, Ayumu ,  NISHIZAWA, Naoki ,  COLE, Derek, Cecil ,  FLINSPACH, Mack ,  SCORAH, Nick ,  BHAT, Abhijit, Suresh

IPC: C07K14/605 ,  A61K38/00

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P 1 - A 1 - A2- A3 - A4- A5 - A6- A7 - A8-A9-A 10- A 11 - A 12- A 13- A 14- A 15-A 16-A 17-A18-A19-A20-A21 -A22-A23-A24-A25- A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P 2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.

公开(公告)号：WO2020027344A1

公开(公告)日：2020-02-06

申请号：PCT/JP2019/031284

申请日：2019-08-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： RATTI, Emiliangelo ,  ASGHARNEJAD, Mahnaz ,  BELFORT, Gabriel

IPC: A61K31/4545 ,  A61K45/06 ,  A61K9/00 ,  A61P25/24

Abstract: The present disclosure relates to methods of treating certain depressive disorders by administration of (4-benzyl-4-hydroxypiperidin-1-yl)(2,4'-bipyridin-3-yl)methanone or a pharmaceutically acceptable salt thereof or (2R)-1-((1-(4-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl)piperidin-4-yl)carbonyl)pyrrolidine-2-carbonitrile or a pharmaceutically acceptable salt thereof.